Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $120.00 | Overweight | Analyst |
| 12/11/2024 | $103.00 → $120.00 | Equal Weight → Overweight | Wells Fargo |
| 6/28/2024 | $96.00 | Outperform | Robert W. Baird |
| 4/11/2024 | $88.00 | Buy | CL King |
| 2/7/2024 | $87.00 | Neutral | BofA Securities |
| 12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
| 12/20/2022 | $73.00 → $72.00 | Buy → Hold | Canaccord Genuity |
| 2/25/2022 | $73.00 → $72.00 | Outperform | Raymond James |
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular Interventional Strategies (VEINS) conference held in Las Vegas, NV. For the millions of patients diagnosed with advanced kidney disease, hemodialysis is a life-saving treatment that repla
Highlights† Reported revenue of $384.2 million, up 13.0%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectivelyGAAP operating margin of 11.1%, compared to 11.0% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.2% in prior year periodGAAP EPS $0.46, down 3.0%Non-GAAP EPS* $0.92, up 6.7%Free cash flow* generation of $141.6 million over first nine months of 2025, up 17.6% year-over-year † Comparisons above are calculated for the current quarter compared with the third quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Const
Transaction supports PENTAX Medical's strategic focus on core flexible reusable endoscopy MONTVALE, N.J., Oct. 15, 2025 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group and a global leader in flexible reusable endoscopy, today announced an asset purchase agreement with Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, for the acquisition of the C2 CryoBalloon™ technology. This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships. The C2 CryoBalloon™ has been part of PENTAX Medical's therapeutic portfolio since 2017, offering a minimally invasive option to treat patient
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
4/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
3/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00
Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously
Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit
Highlights† Reported revenue of $384.2 million, up 13.0%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectivelyGAAP operating margin of 11.1%, compared to 11.0% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.2% in prior year periodGAAP EPS $0.46, down 3.0%Non-GAAP EPS* $0.92, up 6.7%Free cash flow* generation of $141.6 million over first nine months of 2025, up 17.6% year-over-year † Comparisons above are calculated for the current quarter compared with the third quarter of 2024, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts. * Const
SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed
Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. ("Biolife"), a manufacturer of hemostatic devices branded as StatSeal® and WoundSeal®Martha Aronson named as new President and Chief Executive Officer, effective October 3, 2025 † Comparisons above are calculate
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)